Mortality Associated with Hormone Replacement Therapy in Postmenopausal Women

Koo, Yu-Jin; Song, Yong Jung; Na, Yong Jin

doi:10.6118/jksm.2012.18.3.133

Cited by 2 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Like this, actions of estrogen depends on the time of initiation of estrogen therapy in postmenopausal women, and it may be due to endothelial injury, changes in vascular estrogen receptor expression, intracellular signaling which could alter the cardiovascular effects of this steroid hormone 9. Although risk and benefit of HRT since the first announcement of Women's Health Initiative study in 2002 were controversial, hormone replacement therapy in young menopausal women could decrease the morbidity and mortality related to coronary heart disease and stroke 10. Also in one previous study, early menopausal women are known to face more physiological problems than the late menopausal women on their quality of life 11…”

Section: Discussionmentioning

confidence: 99%

Serum Thyroid Stimulating Hormone Levels Are Associated with the Presence of Coronary Atherosclerosis in Healthy Postmenopausal Women

et al. 2016

View full text Add to dashboard Cite

ObjectivesMenopause is a natural aging process causing estrogen deficiency, accelerating atherogenic processes including dyslipidemia. Prevalence of thyroid dysfunction is also high in postmenopausal women, and it is known to elevate the risk of cardiovascular disease (CVD). Therefore, we are to study on the associations in between serum thyroid stimulating hormone (TSH) and prevalence of CVD in postmenopausal women who have normal thyroid function.MethodsWe performed a retrospective review of 247 Korean postmenopausal women who visited the health promotion center from January, 2007 to December, 2009. Postmenopausal women with normal serum TSH were included in the study. Coronary atherosclerosis was assessed by 64-row multidetector computed tomography.ResultsIn multiple linear regression analysis, serum TSH was associated with serum triglyceride (TG) (β = 0.146, P = 0.023). In multiple logistic regression analysis, increasing age and serum TSH were associated with an increased risk of coronary atherosclerosis in euthyroid postmenopausal women (odds ratio [OR] = 1.107 [1.024-1.197], P = 0.011 and OR = 1.303 [1.024-1.658], P = 0.031, respectively).ConclusionsIt revealed that significant predictor of serum TSH was serum TG, and increasing age and TSH were found to have associations with an increased risk of coronary atherosclerosis in euthyroid postmenopausal women. Screening and assessing risks for CVD in healthy postmenopausal women would be helpful before atherosclerosis develops.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Thyroid Stimulating Hormone Levels Are Associated with the Presence of Coronary Atherosclerosis in Healthy Postmenopausal Women

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Especially, postmenopausal osteoporosis, the main disease related to aging in women, is a high-risk disease that decreases bone strength and makes it easier for patients' bones to be fractured 2. Currently, most medications for postmenopausal osteoporosis suppress activity of osteoclasts and cause adverse effects 34. Most widely used medications for postmenopausal osteoporosis are oral and intravenous bisphosphonates, such as alendronate, ibandronate, risedronate, and zoledronate.…”

Section: Introductionmentioning

confidence: 99%

“… 2 Currently, most medications for postmenopausal osteoporosis suppress activity of osteoclasts and cause adverse effects. 3 4 Most widely used medications for postmenopausal osteoporosis are oral and intravenous bisphosphonates, such as alendronate, ibandronate, risedronate, and zoledronate. However, despite their proven safety and efficacy, adverse events such as upper gastrointestinal, impaired renal function, fever, osteonecrosis of jaw, uveitis, and atrial fibrillations have been reported, and thereby their use is limited.…”

Section: Introductionmentioning

confidence: 99%

Cell Therapy Products in Menopausal Medicine

Choi

Kim

et al. 2016

J Menopausal Med

View full text Add to dashboard Cite

The incidence of postmenopausal diseases increases with the age of women. In this review, we introduce cell therapy products, a new treatment for postmenopausal osteoporosis, which often occurs in postmenopausal women. We also figure out the trends of research on cell therapy products and emphasize the necessity and importance of this research for researchers and postmenopausal women. Finally, we suggest the direction for improvement of postmenopausal osteoporosis and research on cell therapy products. We investigated which medication have been used so far. We also examined the development and technical problems of technologies that are currently in use.

show abstract

Mortality Associated with Hormone Replacement Therapy in Postmenopausal Women

Cited by 2 publications

References 15 publications

Serum Thyroid Stimulating Hormone Levels Are Associated with the Presence of Coronary Atherosclerosis in Healthy Postmenopausal Women

Serum Thyroid Stimulating Hormone Levels Are Associated with the Presence of Coronary Atherosclerosis in Healthy Postmenopausal Women

Cell Therapy Products in Menopausal Medicine

Contact Info

Product

Resources

About